To integrate computational chemistry into the study of natural dual COX-2 and 5-LOX inhibitors, you can implement a **multi-target virtual screening** workflow. This approach allows you to computationally screen a library of natural compounds against both enzymes simultaneously to identify "dual-action" candidates before starting wet-lab work.

Here is how you can structure this project plan:

---

### Objective
To identify, extract, and biochemically validate synergistic, natural dual-acting inhibitors of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) using multi-target molecular docking, phytochemical extraction, and cell-free enzymatic assays.

---

### Methodology

The study begins with **multi-target virtual screening** of a targeted library of natural compounds (such as gingerols, curcuminoids, and boswellic acids) drawn from natural product databases. Computational docking is performed against the 3D crystal structures of both target enzymes retrieved from the Protein Data Bank: human COX-2 (e.g., **PDB ID: 5IKQ** or **1CX2** [2.1]) and human 5-LOX (e.g., **PDB ID: 6N2W** or **3V99** [2.2]). Using docking engines such as **AutoDock Vina**, the library is screened against the active sites of both enzymes. 

To identify potential dual inhibitors, a **consensus docking score** is calculated for each ligand. The computational analysis prioritizes compounds exhibiting favorable binding free energies (kcal/mol) and key spatial interactions in both targets, specifically:
* In COX-2: Hydrogen bonding with the key active site residue **Arg120** or **Tyr355** [2.1, 2.3].
* In 5-LOX: Chelation or coordinate bonding with the catalytic **Fe(III) ion** or hydrophobic interactions in the arachidonic acid-binding cavity [2.4].

**Pharmacophore mapping** is then conducted to determine if the top-scoring dual-target ligands share a common geometric arrangement of chemical features (such as hydrogen bond donors/acceptors and aromatic rings) that satisfy the binding pockets of both enzymes. SwissADME is utilized to filter these dual-target hits for optimal drug-likeness (Lipinski’s Rule of 5) and skin permeability ($\log K_p$) to evaluate their suitability for topical or oral anti-inflammatory delivery.

Following the computational identification of the most promising botanical sources containing these dual-target ligands (such as *Boswellia serrata* or *Zingiber officinale*), the plant material undergoes solid-liquid extraction. The resulting crude extract is refined using acid-base partitioning to enrich the organic acid fractions (e.g., boswellic acids) or phenolic fractions (e.g., gingerols). These fractions are then separated using silica gel column chromatography. High-Performance Liquid Chromatography (HPLC) coupled with UV-Vis detection is used to identify and quantify the exact concentration of the computationally predicted dual-inhibitors within your extracts.

Finally, the computational predictions are validated using cell-free, colorimetric or fluorometric **COX-2 and 5-LOX enzymatic inhibitor screening assays**. Purified recombinant human enzymes are incubated with their respective substrates (arachidonic acid) in the presence of serial dilutions of your plant fractions. The rate of prostaglandin (for COX-2) and leukotriene (for 5-LOX) synthesis is measured spectrophotometrically to calculate experimental $IC_{50}$ values for each target. A final mathematical correlation is performed to assess the relationship between the computational multi-target docking scores and the experimental dual-enzyme inhibition profiles, validating the in silico screening pipeline.